GO
Loading...

Cramer Examines BioMarin Pharmaceuticals

Tuesday, 19 Jun 2012 | 6:15 PM ET

Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses his company's efforts to develop treatment products for Lysosomal Storage Disorders. "We are the opposite of big pharma, we look at a significant improvement in a small patient population," says Bienaime.